OIPE 4607

FF

dider the Paperwork Redu	ction Act of 1995, no pe	rsons are required to respond to a colle	PTO/SB/21 (02-04 Approved for use through 07/31/2006. OMB 0651-003 atent and Trademark Office; U.S. DEPARTMENT OF COMMERC ection of information unless it displays a valid OMB control numbe
		Application Number	10/656,715
TRANSM		Filing Date	September 5, 2003
FORI	VI	First Named Inventor	Yang-Dar-Yuan
(to be used for all correspond	dence after initial filing)	Art Unit	1614
		Examiner Name	Amy Lewis
Total Number of Pages in This	s Submission	Attorney Docket Number	600-69-CIP
	El	NCLOSURES (Check all t	that apply)
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/decl Extension of Time Re Express Abandonmen Information Disclosur Certified Copy of Prior Document(s) Response to Missing Incomplete Application Response to Information Disclosur	aration(s) quest  Int Request e Statement rity  Parts/ n  Missing Parts	Drawing(s)  Licensing-related Papers  Petition  Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence A Terminal Disclaimer  Request for Refund  CD, Number of CD(s)  marks  ase apply any dificiencies or overg	After Allowance communication to Technology Center (TC)  Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)  Proprietary Information  Status Letter Other Enclosure(s) (please Identify below): Supplemental Information Disclosure Statement
·	SIGNATUR	E OF APPLICANT, ATTO	DNEV OD AGENT
rm Gabor L. S		L OF AFFLICANT, ATTO	MALI, ON AGENT
dividual name			
gnature	Cialia	i hereses	
ate	Galw	11.0	0.600
		May 8,	7000
-	CERTI	FICATE OF TRANSMISSI	ON/MAILING
nereby certify that this corre ifficient postage as first clase e date shown below.	spondence is being f is mail in an envelope	acsimile transmitted to the USPTC anddressed to: Commissioner for	O or deposited with the United States Postal Service with Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on
	oni Whyte		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**PATENT** 

# MAY 11 7000 BY ATTORNEY DOCKET NO. 600-69-CIP

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applica	ation of	)	Examiner:	Amy Lewis
Yuan, et	al.	) )	Unit:	1614
Serial No.:	10/656,715	) )		
Filed:	September 5, 2003	) )		
For: Compositions and Methods Using Compounds Having Cytochrome P450RAI Inhibitory Activity Co-Administered with Vitamin A				

## FILING OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

Certificate of Mailing

I hereby certify that this correspondence is being deposited on May 8, 2001 with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, Alexandria, VA 22313-1450.

May 8, 2006

Dear Sir:

Attached is a Supplemental Information Disclosure Statement By Applicant for Patent Application 10/656,715, filed September 5, 2003.

#### **REMARKS**

References US 2003/0207937 and Kagechika et al. J. Med. Chem., 31(11): 2182-2192 (1988) are newly submitted.

References Allegretto, et al., J. Biol. Chem., 268(35): 26625-26633 (1993) and Cheng, et al., Biochemical Pharmacology, 22(23): 3099-3108 (1973) were previously submitted in applicant's original Information Disclosure Statement but not fully or correctly identified.

Presently copy of only of the Kagechika et al. reference is submitted because the reference US 2003/0207937 does not require submission of a copy.

Submission of the foregoing documents is not representation that a search was made, or if made, that it was comprehensive, or that no other documents exist which may be material to the above-identified application.

Moreover, the applicant does not concede that the foregoing documents are necessarily prior art to the invention.

Authorization to charge any fees to our deposit account 502362 is hereby granted.

Respectfully submitted,

Date:

By

Gabor L. Szekeres, Registration No. 28,675

Attorney for Applicant

Law Offices of Gabor L. Szekeres 8141 E. Kaiser Boulevard, Suite 112 Anaheim Hills, California 92808

Telephone: (714) 998-3295 Facsimile: (714) 998-3296

Sheet

PTO/SB/O8A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

#### Complete if Known Substitute for form 1449A/PTO **Application Number** 10/656,715 SUPPLEMENTAL Filing Date September 5, 2003 INFORMATION DISCLOSURE First Named Inventor Yang-Dar Yuan Art Unit 1614 STATEMENT BY APPLICANT **Examiner Name Amy Lewis** (Use as many sheets as necessary) Attorney Docket Number 600-69-CIP 2

	U.S. PATENT DOCUMENTS						
Examiner	Cite	Document Number  Number-Kind Code <sup>2</sup> (if known)	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant		
Initials*	No.'	US-2003/0207937	MM-DD-YYYY 11-06-2003	Applicant of Cited Document Vasudevan, et al.	Passages or Relevant Figures Appear		
		US-	11-00-2003	vasuuevaii, et ai.			
		US-					
		US-					
		US-			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
		US-		***************************************			
,		US-					
		US-					
······		US-					
		US-					
		US-					
	1	US-					
		US-					
		US-					
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		US-					
		US-					
		US-					
		US-		**************************************			
		US-					
		US-					

Cite No.'	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind <sup>5</sup> (if known)	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant	T
		MINI-DO-1111	Applicant of Cited Document	Passages or Relevant Figures Appear	
					ļ
					<u> </u>
					<u> </u>
					<u> </u>
			~~.~~		
					<u></u>
					<u></u>
					<u> </u>
		,	(		

	the state of the s		
Examiner		Date	
Signature		Considered	



<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Senter Office that issued the document, by the two-letter code (WIPO Standard ST 3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case, any comments on the amount of time you are required complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES FOR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark office: U.S. DEPARTMENT OF COMMERCE
There the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

				Complete if Known		
	SUPPLEM	1EN	ITAL	Applicant Number	10/656,715	
INFORMATION DISCLOSURE				Filing Date	September 5, 2003	
STATEMENT BY APPLICANT  (use as many sheets as necessary)				First Named Inventor	Yang-Dar Yuan	
			PLICANT	Group Art Unit	1614	
			necessary)	Examiner Name	Amy Lewis	
Sheet	2	of	2	Attorney Docket Number	600-69-CIP	

	OTHER PRIOR ART – NON PATENT LIERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pate(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>			
<u></u>	†	Allegretto, et al., "Transactivation Properties of Retinoic Acid and Retinoid X Receptors in	י 🗀 ו			
i		Mammalian Cells and Yeast - Correlation with Homone Binding and Effects of				
		Metabolism," J. Biol. Chem., 268(35): 26625-26633 (1993).				
		Cheng, et al., "Relationship Between the Inhibition Constant (K1) and the Concentration of				
l		Inhibitor which Causes 50 per cent Inhibition (I50) of an Enzymatic Reaction," Biochemical				
ĺ		Pharmacology, 22(23): 3099-3108 (1973).				
··-··	<b>†</b>	Kagechika, et al., "Retinobenzoic Acids - Structure-Activity Relationships of Aromatic				
ł		Amides with Retinoidal Activity," J. Med. Chem., 31(11): 2182-2192 (1988).				
ļ	<b></b>		<del>   </del>			
1			片			
1						
		<del> </del>	<b>├</b>			
1						
1						
1						
		<u> </u>				
1			IH			
1		ļ ,				
1		}				
			Ш			
Examin	ner	Date				
Signatu	1	Considered				

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.